Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDA
2025-524543-12-00Phase 2Authorised
- Sponsor
- Pirkanmaan hyvinvointialue
- Start
- Mar 2026
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of vancomycin in autoimmune colitis and Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by Pirkanmaan hyvinvointialue. Primary endpoints: Clinical remission with mucosal healing and Gut microbiota composition and function. Planned start Mar 2026; status: authorised.
02
Drugs
vancomycin
03
Conditions
autoimmune colitisPrimary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2025-524543-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524543-12-00.